Cargando…
Involvement of kallikrein‐PAR2‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity
Trastuzumab‐induced cardiotoxicity interferes with continued treatment in approximately 10% of patients with ErbB2‐positive breast cancer, but its mechanism has not been fully elucidated. In this study, we recruited trastuzumab‐treated patients with ≥30% reduction in left ventricular ejection fracti...
Autores principales: | Sasaki, Ritsuko, Kurebayashi, Nagomi, Eguchi, Hidetaka, Horimoto, Yoshiya, Shiga, Takahiro, Miyazaki, Sakiko, Kashiyama, Taku, Akamatsu, Wado, Saito, Mitsue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530879/ https://www.ncbi.nlm.nih.gov/pubmed/35879248 http://dx.doi.org/10.1111/cas.15508 |
Ejemplares similares
-
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021) -
Engineering a Novel Multifunctional Green Fluorescent Protein Tag for a Wide Variety of Protein Research
por: Kobayashi, Takuya, et al.
Publicado: (2008) -
Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis
por: Ohtsu, Hiroshi, et al.
Publicado: (2022) -
Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014) -
Administration of plasma-derived coagulation factor VIII during the perioperative period of mastectomy for breast cancer with acquired von Willebrand syndrome
por: Sasaki, Ritsuko, et al.
Publicado: (2018)